Contact
searchSearch
HMP Global

May 2013 - FRMC

Department

Conference Insider
Three Ways to Improve Medication Nonadherence
05/17/2013
Jill Sederstorm
San Diego—Medication nonadherence is a costly problem in healthcare, but predictive modeling, value-based insurance design (VBID), and the application of gamification could help improve adherence rates. These 3 strategies and the challenges...
San Diego—Medication nonadherence is a costly problem in healthcare, but predictive modeling, value-based insurance design (VBID), and the application of gamification could help improve adherence rates. These 3 strategies and the challenges...
San Diego—Medication...
05/17/2013
First Report Managed Care
Conference Insider
Auvi-Q™ for Type 1 Allergic Reactions and Anaphylaxis
05/17/2013
Tim Casey
San Diego—As many as 6 million people in the United States are at risk of anaphylaxis, and the prevalence is increasing, especially among people <20 years of age, according to several studies. In August 2012, the FDA approved Auvi-Q™...
San Diego—As many as 6 million people in the United States are at risk of anaphylaxis, and the prevalence is increasing, especially among people <20 years of age, according to several studies. In August 2012, the FDA approved Auvi-Q™...
San Diego—As many as 6 million...
05/17/2013
First Report Managed Care
Conference Insider
Rare Diseases and Orphan Drugs: Status, Reimbursement, and Management
05/17/2013
Tori Socha
San Diego—There are approximately 7000 diseases that are categorized as rare, but only 5% of those have approved treatments. The 1984 amendment to the Orphan Drug Act of 1983 (ODA) defined a rare disease as one that affects 200,000 people in...
San Diego—There are approximately 7000 diseases that are categorized as rare, but only 5% of those have approved treatments. The 1984 amendment to the Orphan Drug Act of 1983 (ODA) defined a rare disease as one that affects 200,000 people in...
San Diego—There are...
05/17/2013
First Report Managed Care
Conference Insider
Results of the EMD Serono Specialty Digest™, 9th Edition
05/17/2013
Tim Casey
San Diego—With major provisions from the Patient Protection and Affordable Care Act becoming effective next year, the healthcare industry is facing a challenge keeping medication costs in check due to, in part, the proliferation of expensive...
San Diego—With major provisions from the Patient Protection and Affordable Care Act becoming effective next year, the healthcare industry is facing a challenge keeping medication costs in check due to, in part, the proliferation of expensive...
San Diego—With major provisions...
05/17/2013
First Report Managed Care
Conference Insider
Rapidly Evolving Specialty Pharmacy Industry
05/17/2013
Mary Beth Nierengarten
San Diego—With the dominance of specialty drugs driving increasing prescription medication expenditures, pharmacists need to prepare for significant growth in specialty pharmaceuticals and its impact on medication benefit plans.
San Diego—With the dominance of specialty drugs driving increasing prescription medication expenditures, pharmacists need to prepare for significant growth in specialty pharmaceuticals and its impact on medication benefit plans.
San Diego—With the dominance of...
05/17/2013
First Report Managed Care
Conference Insider
Identifying the Economic Burden of Pain
05/17/2013
Tori Socha
San Diego—Pain is challenging to treat and the healthcare cost burden of pain is substantial. According to researchers, understanding the dynamics of the economic burden of pain will help providers and payers allocate resources more...
San Diego—Pain is challenging to treat and the healthcare cost burden of pain is substantial. According to researchers, understanding the dynamics of the economic burden of pain will help providers and payers allocate resources more...
San Diego—Pain is challenging to...
05/17/2013
First Report Managed Care
Conference Insider
DMD Early Adherence as Predictor of Future Adherence
05/17/2013
Tori Socha
San Diego—Multiple sclerosis generally presents in young adults, resulting in a greater loss of productivity and quality of life compared with other diseases. Frequency of relapses can be reduced with use of disease-modifying drugs (DMDs),...
San Diego—Multiple sclerosis generally presents in young adults, resulting in a greater loss of productivity and quality of life compared with other diseases. Frequency of relapses can be reduced with use of disease-modifying drugs (DMDs),...
San Diego—Multiple sclerosis...
05/17/2013
First Report Managed Care
Department
Oral Medication Aubagio® Approved for Multiple Sclerosis
05/17/2013
Tim Casey
San Diego—In the past, patients with multiple sclerosis were required to administer medications intravenously or via injections, a painful process for some, but they had no other choices. Now, though, treatment options have expanded into oral...
San Diego—In the past, patients with multiple sclerosis were required to administer medications intravenously or via injections, a painful process for some, but they had no other choices. Now, though, treatment options have expanded into oral...
San Diego—In the past, patients...
05/17/2013
First Report Managed Care
Guideline-Preferred ART Regimens for Patients with HIV
05/17/2013
Tori Socha
San Diego—In March 2012, the U.S. Department of Health & Human Services (HHS) issued guidelines for the use of antiretroviral therapy (ART) in patients with HIV that recommend 4 specific preferred ART regimens for ART-naïve patients.
San Diego—In March 2012, the U.S. Department of Health & Human Services (HHS) issued guidelines for the use of antiretroviral therapy (ART) in patients with HIV that recommend 4 specific preferred ART regimens for ART-naïve patients.
San Diego—In March 2012, the...
05/17/2013
First Report Managed Care
Expenditures in Patients Taking Noninsulin Antidiabetic Agents
05/17/2013
Tori Socha
San Diego—Healthcare decision makers face challenges in optimizing disease management in patients with type 2 diabetes mellitus (T2DM). Increasing healthcare expenditures can be attributed, in part, to the costs, including medical and...
San Diego—Healthcare decision makers face challenges in optimizing disease management in patients with type 2 diabetes mellitus (T2DM). Increasing healthcare expenditures can be attributed, in part, to the costs, including medical and...
San Diego—Healthcare decision...
05/17/2013
First Report Managed Care

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Katie Hayes, MJ
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
Katie Hayes, MJ
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
Katie Hayes, MJ
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Improving Health Outcomes Through Early COPD and Asthma Intervention
10/04/2024
Hannah Musick
Research published in the New England Journal of Medicine shows that early diagnosis and treatment of undiagnosed COPD or asthma can reduce health care utilization for respiratory illness and improve overall health outcomes.
Research published in the New England Journal of Medicine shows that early diagnosis and treatment of undiagnosed COPD or asthma can reduce health care utilization for respiratory illness and improve overall health outcomes.
Research published in the New...
10/04/2024
First Report Managed Care
News
Advances in Factor IX Therapy Offer New Hope for Hemophilia B Treatment
10/23/2024
Lisa Kuhns, PhD, MD
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise improved treatment for hemophilia B.
New factor IX therapies promise...
10/23/2024
First Report Managed Care
News
JAK Inhibitor Improves Symptoms in Patients With Psoriatic Arthritis and Axial Involvement
04/21/2023
Jolynn Tumolo
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing upadacitinib to placebo and adalimumab, upadacitinib improved symptoms in patients with psoriatic arthritis and axial involvement.
In two phase 3 studies comparing...
04/21/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
Conference Coverage
Significant Number of Solid Tumor Drug Approvals Added Complexity to Existing Regimens
06/08/2023
Maria Asimopoulos
A significant portion of drug approvals for nonhematologic solid cancers in the last 12 years were for indications which added to existing regimens, which could increase costs and exposure to side effects, researchers said.
A significant portion of drug approvals for nonhematologic solid cancers in the last 12 years were for indications which added to existing regimens, which could increase costs and exposure to side effects, researchers said.
A significant portion of drug...
06/08/2023
First Report Managed Care

May 2013 Volume 10 Issue 5

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use